RYAH Group Inc. (CSE: RYAH) Globally Unlocking Data in the Complete Therapeutic Plant Lifecycle

  • Providing a holistic approach to therapeutic plant treatment by unlocking data from seed to consumption
  • RYAH Group is providing needed dosing devices globally to drive innovation and deliver cutting edge plant-based medical solutions globally 
  • With over 200k registered users, RYAH Group is one of the largest plant-based medicine databases in the world and regularly releases and shares valuable insights collected

RYAH Group (CSE: RYAH), formerly RYAH Medtech, is leading the way forward by providing a holistic approach to therapeutic plant treatment by unlocking the data in the complete plant lifecycle (seed to consumption). Known for its high-quality information and digital health care analytics, RYAH Group is positively impacting the future treatment of patients for various medical conditions worldwide. The Company has globally expanded its reach in IoT hardware, software, and data analytics making it possible for researchers to significantly reduce variations in patient-related trials. 

Whether combining forces with the University of Milan to rigorously map out the behavior of cannabis strains to create accurate milligram dosing (https://ibn.fm/ksB18), providing the necessary dose-measuring devices to an oncology clinic in the UK for the largest of its kind cannabis clinical trial (https://ibn.fm/KkLOq), or partnering with companies like Medical Kiwi to drive innovation and deliver cutting edge plant-based medical solutions in New Zealand (https://ibn.fm/FlGbb) – RYAH Group is paving the way for a better understanding and better outcomes of plant-based treatments globally.

This is achieved by having multiple touch points and working with multiple players throughout the plant’s lifecycle. The Company has partnered with growers, dispensaries, clinical trials, researchers, and patients to collect seed-to-consumption data. This creates a deeper understanding of the roles of formulations and dosing in treatments.

In order to collect the data, RYAH Group has created smart devices combined with artificial intelligence and an integrated platform that allow both the patient and doctor to regulate prescriptions safely and seamlessly. The HIPAA-compliant patient data is monitored by an AI platform throughout the patient’s session and formulation lifecycle providing additional data that is fed into the Cloud that continues the process. 

The Company’s smart devices include: 

  • RYAH Smart Patch – used primarily by physical therapists and cannabis-treated patients, pain relief professionals and occupational therapists for site-specific therapy to treat a variety of conditions
  • RYAH Dry-herb Inhaler – measures inhalations to deliver precise and predictable results
  • RYAH Pen – oral drug dispenser connected to a mobile application, allows users to track dosing and usage statistics
  • RYAH MD – platform for doctors to remotely monitor and control their patients’ dosing regimen with RYAH’s suite of dose measuring products

RYAH Group uses a data-driven approach that combines dosing data, lab test information, and consumer feedback. Big data and AI are used to discover breakthroughs and better enable providers to create highly personalized dosing regimens for the end users. With over 200k registered users, RYAH Group is one of the largest plant-based medicine databases in the world and regularly releases and shares valuable insights collected. These data reports are released monthly and available to everyone at www.RYAHGroup.com/news

In the U.S., study has been limited for the last 50 years due to federal regulations. But change is on the horizon (https://ibn.fm/O1efL). Researchers in the U.S., currently restricted to federally cultivated cannabis, will soon have access to the therapeutic plants and products that end users are actually using. Cannabis research in 2022 will be conducted in a way that will benefit the consumer and lead to better medicinal products and safer recommendations. RYAH is ready and has the necessary IoT devices needed to ensure these future studies collect and analyze the data in the most effective way possible.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050